Summit Therapeutics/SMMT

$2.92

-0.51%
-
1D1W1MYTD1YMAX

About Summit Therapeutics

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.

Ticker

SMMT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Duggan

Employees

105

Headquarters

Menlo park, United States

SMMT Metrics

BasicAdvanced
$1.7B
Market cap
-
P/E ratio
-$0.17
EPS
-1.39
Beta
-
Dividend rate
$1.7B
-1.39126
$5.39
$1.50
2.4M
6.966
226.193
226.193
-118.81%
-53.76%
-130.59%
-59.38%
37.949
39.63
-100%
91.03%

What the Analysts think about SMMT

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
128.42% upside
High $8.00
Low $5.00
$2.92
Current price
$6.67
Average price target

SMMT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$43M
18.9%
Profit margin
0%
NaN%

SMMT Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0%
QuarterlyAnnual
Q1 24
Q2 24
Actual
-$0.06
-
Expected
-$0.06
-$0.06
Surprise
0%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Summit Therapeutics stock?

Summit Therapeutics (SMMT) has a market cap of $1.7B as of May 30, 2024.

What is the P/E ratio for Summit Therapeutics stock?

The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of May 30, 2024.

Does Summit Therapeutics stock pay dividends?

No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Summit Therapeutics dividend payment date?

Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.

What is the beta indicator for Summit Therapeutics?

Summit Therapeutics (SMMT) has a beta rating of -1.39. This means that it has an inverse relation to market volatility.

What is the Summit Therapeutics stock price target?

The target price for Summit Therapeutics (SMMT) stock is $6.67, which is 105.86% above the current price of $3.24. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Summit Therapeutics stock

Buy or sell Summit Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing